Immunolight’s X-PACT Paper Wins SEAAPM 2017 Best Paper Award

Immunolight’s X-PACT Paper Wins SEAAPM 2017 Best Paper Award

The South Eastern Chapter of the American Association of Physicists in Medicine (SEAAPM) has chosen Immunolight’s paper, X-Ray Psoralen Activated Cancer Therapy to receive it’s 2017’s best paper award.

Immunolight Named Detroit’s Most Innovative Company

Immunolight Named Detroit’s Most Innovative Company

We are excited and honored to announce that Crain’s Detroit Business News has named Immunolight LLC as the most innovative company in Detroit for 2016. The award is the result of an independent annual survey called the Eureka Index that scores companies on READ MORE

Now Recruiting for Phase II Studies

Now Recruiting for Phase II Studies

In collaboration with the NC State College of Veterinary Medicine, Immunolight therapy for canine cancer is now recruiting potential candidates for our Phase II Study. After a successful Phase I Safety Study, the goal of this new research project is to continue studying and refining Immunolight Therapy, an innovative approach to cancer treatment.

Immunolight Announces a New Psoralen Mechanism of Action Discovered that Attacks Breast Cancer Cells

Immunolight Announces a New Psoralen Mechanism of Action Discovered that Attacks Breast Cancer Cells

Immunolight LLC, an emerging leader in the development of a breakthrough platform technology leveraging the latest advances in energy transfer, has announced research about a new mode of action utilizing psoralen, a naturally occurring compound found in broccoli and figs, that may shed new light on the fight against cancer.